Jak‐stat Pathway and Epigenetic Regulators Are Critical Players in Bi‐alcl Pathogenesis?

Laurent, Camille; Nicolae, Alina; Bras, Fabien Le; Haı̈oun, Corinne; Fataccioli, Virginie; Amara, Nadia; Adélaı̈de, José; Guillé, Arnaud; Colella, Jean-Marc Schiano de; Tesson, Bruno; Traverse-Gléhen, Alexandra; Chenard, Marie-Pierrette; Mescam, Lénaïg; Moreau, Anne; Chassagne‐Clément, Catherine; Somja, Joan; Escudié, Frédérice; André, Marc; Martin, Nicolas; Hamy-Petit, A-S; Reyal, Fabien; Croix, Manon; Birnbaum, Daniel; Brousset, Pierre; Xerri, Luc; Gaulard, Philippe

doi:10.1002/hon.16_2630

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…BIA-ALCL cells possess a specific pattern of genetic alterations, mainly including JAK-STAT, DNMT3A, PD-L1 chromosomal copy number aberrations (CNAs), chromosome 20q loss, (CA9) overexpression, TP53 mutations (Wang et al, 2022), and HLA polymorphism (Tevis et al, 2019). Among these, the constitutive activation of JAK-STAT3 pathway (peculiar in T-cell activation in response to inflammatory stimuli) has recently been explored and identified as a potential key mediator in BIA-ALCL pathogenesis and may even provide a new therapeutic target (Blombery et al, 2016(Blombery et al, , 2018Di Napoli et al, 2018;Oishi et al, 2018;Laurent et al, 2020). The hypothesis is that in genetically susceptible patients, dysregulation of the JAK1/STAT3 pathway may occur, predisposing the emergence and proliferation of CD30+ monoclonal and ALK-negative cells in response to inflammatory/irritative stimuli caused by the implant (Laurent et al, 2020;Wang et al, 2022).…”

Section: Genetic Factors Predisposing To the Development Of Breast Im...mentioning

confidence: 99%

“…Among these, the constitutive activation of JAK-STAT3 pathway (peculiar in T-cell activation in response to inflammatory stimuli) has recently been explored and identified as a potential key mediator in BIA-ALCL pathogenesis and may even provide a new therapeutic target (Blombery et al, 2016(Blombery et al, , 2018Di Napoli et al, 2018;Oishi et al, 2018;Laurent et al, 2020). The hypothesis is that in genetically susceptible patients, dysregulation of the JAK1/STAT3 pathway may occur, predisposing the emergence and proliferation of CD30+ monoclonal and ALK-negative cells in response to inflammatory/irritative stimuli caused by the implant (Laurent et al, 2020;Wang et al, 2022). JAK-STAT3 mutations, however, are present in only 43% of BIA-ALCL, indicating that other mechanisms are also very important, including genetic susceptibility (Decoster et al, 2021).…”

Section: Genetic Factors Predisposing To the Development Of Breast Im...mentioning

confidence: 99%

See 1 more Smart Citation

BIA-ALCL in patients with genetic predisposition for breast cancer: our experience and a review of the literature

Carbonaro

Accardo

Mazzocconi

et al. 2023

European Journal of Cancer Prevention

View full text Add to dashboard Cite

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an emerging non-Hodgkin’s lymphoma that occurs exclusively in patients with breast implants. The estimated risk of developing BIA-ALCL from exposure to breast implants is largely based on approximations about patients at risk. There is a growing body of evidence regarding the presence of specific germline mutations in patients developing BIA-ALCL, rising interest regarding possible markers of genetic predisposition to this type of lymphoma. The present paper focuses attention on BIA-ALCL in women with a genetic predisposition for breast cancer. We report our experience at the European Institute of Oncology, Milan, Italy, describing a case of BIA-ALCL in a BRCA1 mutation carrier who developed BIA-ALCL 5 years after implant-based post mastectomy reconstruction. She was treated successfully with an en-bloc capsulectomy. Additionally, we review the available literature on inherited genetic factors predisposing to the development of BIA-ALCL. In patients with genetic predisposition to breast cancer (mainly TP53 and BRCA1/2 germline mutations), BIA-ALCL prevalence seems to be higher and time to onset appears to be shorter in comparison to the general population. These high-risk patients are already included in close follow-up programs allowing the diagnosis of early-stage BIA-ALCL. For this reason, we do not believe that a different approach should be followed for postoperative surveillance.

show abstract

Section: Genetic Factors Predisposing To the Development Of Breast Im...mentioning

confidence: 99%

Section: Genetic Factors Predisposing To the Development Of Breast Im...mentioning

confidence: 99%

BIA-ALCL in patients with genetic predisposition for breast cancer: our experience and a review of the literature

Carbonaro

Accardo

Mazzocconi

et al. 2023

European Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

Jak‐stat Pathway and Epigenetic Regulators Are Critical Players in Bi‐alcl Pathogenesis?

Abstract: 201

Cited by 1 publication

References 0 publications

BIA-ALCL in patients with genetic predisposition for breast cancer: our experience and a review of the literature

BIA-ALCL in patients with genetic predisposition for breast cancer: our experience and a review of the literature

Contact Info

Product

Resources

About